BBI608 : Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
Adccytotoxin Signal
An estimated 29% of currently approved drugs are enzyme inhibitors of which approximately 1/3 are kinase inhibitors.
